Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?
NCT03094442
Withdrawn
The primary aim is to evaluate whether standard administration of Dexamethasone at the time of general anesthesia induction at the time of minimally invasive sacrocolpopexy (MISC) would result in improved quality of recovery (QoR).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/04/2020
Locations: Cleveland Clinic Florida, Weston, Florida
Conditions: Quality of Life, Pelvic Organ Prolapse, Prolapses, Vaginal Vault
Register for Updates
Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
NCT02034019
Completed
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2020
Locations: Texan Eye / Keystone Research, Ltd., Austin, Texas
Conditions: Post Ocular Surgical Inflammation and Pain
Register for Updates
Effects of Dry Eye Treatments on the Ocular Surface
NCT01797822
Completed
The purpose of this study is to evaluate whether, in people with dry eye syndrome, over the counter artificial tears and the prescription eye drop, dexamethasone, change or effect the eyes response to a low humidity environment. It is known that irritation from dry eye can be improved by over the counter artificial tears because they wet and lubricate the eyes. The prescription eye drop, dexamethasone, can also improve eye irritation by decreasing the inflammation that develops in dry eye. Thus... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2020
Locations: Baylor College of Medicine, Alkek Eye Center, Houston, Texas
Conditions: Keratoconjunctivitis Sicca, Dry Eye Syndrome
Register for Updates
Liposomal Bupivacaine Versus Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Total Knee Arthroplasty
NCT02624856
Withdrawn
The purpose of this study is to compare the efficacy and duration of pain relief after total knee arthroplasty provided by a single injection of liposomal bupivacaine (EXPAREL®) versus standard bupivacaine with an adjuvant, dexamethasone when administered as a quadriceps sparing femoral nerve block and periarticular injection. It is hypothesized that liposomal bupivacaine is superior to standard bupivacaine with dexamethasone and will decrease time to discharge readiness.
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
01/22/2020
Locations: Albany Medical Center, Albany, New York
Conditions: Osteoarthritis, Pain, Postoperative
Register for Updates
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01731886
Completed
The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2020
Locations: Columbia University, New York, New York
Conditions: Multiple Myeloma
Register for Updates
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
NCT01983969
Completed
The goal of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab. Researchers also want to learn about the safety and level of effectiveness of this combination.
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
01/14/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancers, Lymphoma
Register for Updates
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00772915
Completed
RATIONALE: Lenalidomide and dexamethasone may stop the growth of multiple myeloma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works with or without dexamethasone in treating patients with newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/09/2020
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma
NCT00166439
Completed
The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/06/2020
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Lymphoma
Register for Updates
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
NCT01887587
Terminated
This is a phase I study of vincristine, doxorubicin and dexamethasone (modified VXD) plus MLN9708 in adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma, lymphoblastic lymphoma or mixed phenotype acute leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2019
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
Register for Updates
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02404220
Terminated
The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute lymphoblastic leukemia (ALL). This is a dose escalation study in which after 2 induction cycles participants may be put on maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2019
Locations: City of Hope, Duarte, California +12 locations
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery
NCT04205916
Recruiting
To evaluate the safety and ocular efficacy of Dextenza in combination with an intracameral antibiotic and NSAID in controlling post-operative ocular pain and inflammation compared to standard of care topical therapy in patients undergoing bilateral cataract surgery.
Gender:
ALL
Ages:
Between 22 years and 100 years
Trial Updated:
12/17/2019
Locations: Ophthalmic Consultants of Long Island, Garden City, New York
Conditions: Patient Preference
Register for Updates
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
NCT00581776
Completed
Patients will receive Rituximab, Bortezomib, cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone in three week intervals for 6 cycles; then rituximab consolidation (weekly x 4) , then one dose of rituximab every 12 weeks until 5 years or disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2019
Locations: University Of Wisconsin Cancer Center, Madison, Wisconsin
Conditions: Mantle Cell Lymphoma
Register for Updates